Cryoport Enters Strategic Partnership with Worthington Industries

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-05-04-2016
Volume 11
Issue 5

Worthington’s CryoScience by Taylor Wharton business will design and manufacture biostorage and logistics equipment for use in Cryoport’s life-sciences cryogenic logistics solutions.

Cryoport, a cryogenic logistics company, announced on April 13, 2016 that it has entered into a strategic partnership with Worthington Industries, a maker of cryogenic storage vessels and equipment. Through this partnership, Worthington’s CryoScience by Taylor Wharton business will design and manufacture biostorage and logistics equipment for use in Cryoport’s life-sciences cryogenic logistics solutions, Cryoport said in a press announcement.

Cryoport’s proprietary cold chain logistics solutions protect frozen life-sciences commodities from adverse thermal excursions during clinical development through commercial manufacture, thereby contributing to transport, storage, and efficacy. Through its recently acquired CryoScience by Taylor Wharton product line, Worthington manufactures cold chain storage and transport vessels and equipment that transport biological commodities. According to Cryoport, this partnership gives Cryoport the opportunity to expand into other logistics areas such as storage, thereby advancing their offerings in storage and fulfillment.

“This strategic partnership between Cryoport and Worthington will help meet the quality and reliability demands of the growing life-sciences industry. Cold chain logistics has become a strategic consideration, as there is an ever-increasing need for cryogenic logistics in the biopharma, animal health, cellular therapy and reproductive medicine markets,” said Andrew Pazahanick, vice-president and general manager of Worthington’s CryoScience by Taylor-Wharton business, in a press announcement.

Source: Cryoport

 

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Related Content